If understanding the inner workings of the brain is on your mind, now is the time to explore the Banner-ASU Neuroscience Scholars program. Top-achieving college undergraduate and graduate science students are eligible to apply for the paid eight-week training program. Applications must be received by March 1.Continue reading
Author Archive: AZBio
Opportunity Alert: Arizona Biomedical Research Centre Research Grants
The Arizona Biomedical Research Centre is soliciting applications from eligible entities to fill the FY2022 Research Grant Cohort. Letters of Intent for New Investigator Awards (NIA) or Investigator Grants (IG) will be accepted starting Wednesday, January 5, 2022 through 3:00 p.m. MST, January 19, 2022. Instructions and application materials can be found at https://portal.ecivis.com. The solicitation number is RFGA2022-010.Continue reading
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA to lower cholesterol and keep it low with two doses a year
For over 50 years, Novartis has developed innovative medicines to treat cardiovascular disease. Building on this legacy, I am reaching out to share the news that Novartis received approval from the U.S. Food and Drug Administration (FDA) for Leqvio® (inclisiran), the first and only small interfering RNA (siRNA) to provide effective and sustained reduction in low-density lipid cholesterol (LDL-C), commonly referred to as “bad cholesterol,” as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality has not yet been determined but is being explored in clinical trials currently underway.
The United States spends over $125 billion on direct medical expenses for ASCVD care each year, and heart disease and stroke represent the largest medical expenditures in the country. Beyond direct healthcare costs, heart disease and stroke have been estimated to result in $138 billion annually in lost productivity.
2022 – Focused on the Year Ahead
2021 was a challenging year in many ways. It was also a year when AZBio Members stepped up to meet these challenges. As we look forward to 2022, we are focused on AZBio’s vision of Arizona becoming a top-ten bioscience state. We invite you to learn more about how you can get engaged with AZBio in 2022 and participate in focus initiatives designed to move us toward the top-ten. Continue reading
TGen-UArizona Medical School Study Points to Possible new Treatment Options for Breast Cancer Patients
Cxcl10 protein can indicate both positive and negative directions of cancer trajectoryContinue reading
HTG Completes HTP Product Next-Phase Development Milestone
Expands Potential Market and Study Opportunities for HTG Transcriptome Panel
Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19
Dec 22. 2021 – Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Paxlovid is available by prescription only and should be initiated as soon as possible after diagnosis of COVID-19 and within five days of symptom onset. Continue reading
TGen Helps Develop Analysis Tool. Leading to More-Accurate evaluation of New Brian Tumor Treatments and Individual Estimates of Survival
‘Nomograms’ accounting for sex differences in the design of clinical trials should help deliver new precision treatments to glioblastoma patientsContinue reading
The MedTech Conference Plans to Return to Boston in 2022 with a Strong In-Person Presence
WASHINGTON, D.C. – The MedTech Conference, powered by the Advanced Medical Technology Association (AdvaMed), announced today it will return to Boston from October 24-26, 2022, with hopes of reconvening the industry after two unconventional years. The annual three-day event provides world-class programming, networking, and business development opportunities for the global medical technology community. The conference will once again offer options for virtual attendance while encouraging safe in-person participation.
Respiratory Tract Bacterial Extracts Could Prevent COVID-19
Researchers from the UArizona College of Medicine – Tucson found that the bacterial lysate OM-85 blocked SARS-CoV-2 infection by decreasing the ability of the coronavirus to bind to the lung cell surface receptor ACE2.Continue reading